Outlook Therapeutics (OTLK) Notes Payables (2015 - 2026)
Outlook Therapeutics (OTLK) reported Notes Payables of $9.8 million for Q1 2026, down 17.96% year-over-year from $12.0 million in Q1 2025, and down 73.15% quarter-over-quarter from $36.7 million in Q4 2025.
Outlook Therapeutics (OTLK) Notes Payables (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has 12 years of Notes Payables data on file, last reported at $9.8 million in Q1 2026.
- Notes Payables for Q1 2026 came in at $9.8 million, down 17.96% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.8 million (down 17.96% YoY), and the FY2025 annual result was $29.9 million, up 1.72% from the prior year.
- Notes Payables eased to $9.8 million in Q1 2026 per OTLK's latest filing, from $36.7 million in the prior quarter.
- Over five years, Notes Payables peaked at $44.7 million in Q1 2024 and troughed at $9.8 million in Q1 2026.
- A 5-year average of $26.4 million and a median of $30.3 million in 2024 frame the typical range for Notes Payables.
- The sharpest annual moves came in 2022 and 2025: Notes Payables surged 1107.15% in 2022, then sank 73.18% in 2025.
- A 5-year view of Notes Payables shows it stood at $10.9 million in 2022, then jumped by 234.8% to $36.5 million in 2023, then dropped by 15.87% to $30.7 million in 2024, then increased by 19.24% to $36.7 million in 2025, then slumped by 73.15% to $9.8 million in 2026.
- Business Quant data shows OTLK's Notes Payables at $9.8 million in Q1 2026, $36.7 million in Q4 2025, and $29.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Outlook Therapeutics | 51.56 Mn | 43.81 Mn | -21,888.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.85 Mn |
| Dec 31, 2025 | 36.66 Mn |
| Sep 30, 2025 | 29.95 Mn |
| Jun 30, 2025 | 14.00 Mn |
| Mar 31, 2025 | 12.00 Mn |
| Dec 31, 2024 | 30.74 Mn |
| Sep 30, 2024 | 29.44 Mn |
| Jun 30, 2024 | 32.43 Mn |
| Mar 31, 2024 | 44.75 Mn |
| Dec 31, 2023 | 36.54 Mn |
| Sep 30, 2023 | 35.55 Mn |
| Jun 30, 2023 | 34.73 Mn |
| Mar 31, 2023 | 31.82 Mn |
| Sep 30, 2022 | 10.92 Mn |
| Jun 30, 2022 | 10.46 Mn |
| Mar 31, 2022 | 22.78 Mn |
| Dec 31, 2021 | 12.72 Mn |
| Sep 30, 2021 | 904,200.00 |
| Jun 30, 2021 | 11.55 Mn |
| Mar 31, 2021 | 11.18 Mn |